Stocks · News reference

Hemab Therapeutics Announces First Healthy Volunteer Dosed In Phase 1 Trial Of HMB-003 For Heavy Menstrual Bleeding; Says Results Expected No Later Than Mid-2027

2026-09-17 12:04:23 UTCBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.ai2026-11-04 22:31:57 UTC
Hemab Therapeutics to Present Clinical and Preclinical Data at 68th ASH Annual Meeting
Hemab Therapeutics announced it will present data from multiple pipeline programs at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2026.
COAG
Benzinga2026-11-04 14:13:25 UTCBenzinga Newsdesk
Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting
COAG
Fiscal.ai2026-11-03 14:02:15 UTC
Hemab Therapeutics to Host Third Quarter 2026 Financial Results Conference Call
Hemab Therapeutics has scheduled a conference call for November 10, 2026, to discuss its financial results and provide a corporate update for the third quarter ended September 30, 2026.
COAG
Fiscal.ai2026-10-29 13:03:32 UTC
J.P. Morgan and Rodman & Renshaw Initiate Coverage on Hemab Therapeutics Holdings, Inc.
J.P. Morgan and Rodman & Renshaw have initiated research coverage on Hemab Therapeutics Holdings, Inc. with positive ratings and specific price targets.
COAG
Benzinga2026-10-15 17:06:02 UTCBenzinga Newsdesk
Hemab Therapeutics shares are trading higher after JP Morgan initiated its coverage on the stock with an Overweight rating and announced a price target of $70.
COAG
Benzinga2026-10-15 13:14:08 UTCBenzinga Newsdesk
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70
COAG